A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism

Journal of Child and Adolescent Psychopharmacology

Volumn 25, Issue 7, 2015, Pages 585-588

  Du, Lin ^a   Shan, Ling ^a   Wang, Bing ^a   Li, Honghua ^a   Xu, Zhida ^b   Staal, Wouter G ^c   Jia, Feiyong ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; LOOP DIURETIC AGENT;

ABSENCE OF SIDE EFFECTS; APPLIED BEHAVIOR ANALYSIS; ARTICLE; AUTISM; AUTISM ASSESSMENT; AUTISM BEHAVIOR CHECKLIST; BEHAVIORAL SCIENCE; CHILD; CHILDHOOD AUTISM RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PILOT STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; AUTISTIC DISORDER; BEHAVIOR THERAPY; CHECKLIST; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; PROCEDURES; PSYCHOLOGICAL RATING SCALE;

AUTISTIC DISORDER; BEHAVIOR THERAPY; BUMETANIDE; CHECKLIST; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84941951806     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2015.0045     Document Type: Article

References (17)

1. Breidbord J, Croudace TJ: Reliability generalization for childhood autism rating scale. J Autism Dev Disord 43:2855-2865, 2013.
2. Busner J, Targum SD: The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28-37, 2007.
3. Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr 2:70, 2014.
4. Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, Delpire E, Jensen FE, Staley KJ: NKCC1 transporter facilitates seizures in the developing brain. Nat Med 11:1205-1213, 2005.
5. Ganz ML: The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med 161:343-349, 2007.
6. Jesner OS, Aref-Adib M, Coren E: Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 24:CD005040, 2007.
7. Lehmann K, Steinecke A, Bolz J. GABA through the ages: Regulation of cortical function and plasticity by inhibitory interneurons. Neural Plast 2012:892784, 2012.
8. Lemonnier E, Ben-Ari Y: The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 99:1885-1888, 2010.
9. Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, Hadjikhani N, Ben-Ari Y: A randomized controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2:e202, 2012.
10. MarteletoMR, PedromônicoMR:Validity ofAutismBehaviorChecklist (ABC): Preliminary study. Rev Bras Psiquiatr 27:295-301, 2005.
11. Myers SM, Johnson CP: American Academy of Pediatrics Council on Children with Disabilities: Management of children with autism spectrum disorders. Pediatrics 120:1162-1182, 2007.
12. Nardou R, Ben-Ari Y, Khalilov I: Bumetanide, an NKCC1 antagonist, does not prevent form, ation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus. J Neurophysiol 101:2878-2888, 2009.
13. Rutter M, Bishop D, Pine D, Scott, Scott S, Stevenson J, Taylor E, Thapar A: Rutter's Child and Adolescent Psychiatry, 5th ed. Part IV: Clinical Syndromes, 46 Autism Spectrum Disorders. Hoboken, NJ: John Wiley & Sons, 2011.
14. Sharma A, Shaw SR: Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: A metaanalysis. J Pediatr Health Care 26:291-299, 2012.
15. Stankovic M, Lakic A, Ilic N: Autism and autistic spectrum disorders in the context of new DSM-V classification, and clinical and epidemiological data. Srp Arh Celok Lek 140:236-243, 2012.
16. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, Khalilov I, Tsintsadze V, Brouchoud C, Chazal G, Lemonnier E, Lozovaya N, Burnashev N, Ben-Ari Y: Oxytocin-mediated GABA inhibition during delivery attenuates autism patho-genesis in rodent offspring. Science 343:675-679, 2014.
17. Walsh MB: The top 10 reasons children with autism deserve ABA. Behav Anal Pract 4:72-79, 2011.